Mandate

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.

The transaction is subject to customary regulatory approvals.

Sertion is a leading Nordic specialist in complex pipework services, serving a broad range of commercial, industrial and infrastructure end-markets where reliability, technical expertise and safety are essential. The group operates across the full pipework value chain – from engineering and prefabrication to installation, service and ongoing operations – and delivers its services through 16 local entities and approximately 1,000 employees in Sweden, Norway and Denmark. Sertion is headquartered in Stockholm, has a turnover of approximately SEK 3 billion and is active in the design, installation and servicing of water, heating and sanitation systems, industrial piping and energy gas solutions.

Vinge’s team primarily consisted of Christina Kokko, Desirée Hagenfeldt, Elsie Nassar, Nicolina Lavdas, Anna Neubüser and Lucas Eriksson (M&A), David Olander (Competition Law and FDI), Linn Adelwald and William Carlberg Johansson (Banking and Finance), as well as Emelie Schoning and Jasmina Skandrani (Project Assistants).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026